SAFE Pharmaceutical Services Corp. (SAFE), an AAALAC accredited China-based full service CRO, announces its successful acquisition of series D financing, further accelerating growth into a pre-IPO global company. This round of financing of about $71M is jointly funded by the SDIC Venture Capital and China's state-owned capital venture fund. This firmly supports SAFE’s aggressive reach into the international market with the expansion of experimental facilities for the next generation cell and gene therapy drugs technology platform.

Yang Liu, Founder and CEO of SAFE, “express(es) my thanks for the continued support of SAFE’s existing and new shareholders. We move forward in continued growth throughout the entire industry chain of innovative drug R&D coupled with our rich experience in China and US regulatory submissions.”